Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy
NCT03558997 · View on ClinicalTrials.gov ↗
Study Summary
The primary objective is to assess whether 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass Subcutaneous Immunotherapy (SCIT) improves upon the efficacy of Timothy Grass SCIT to reduce provoked allergic rhinitis symptoms, as measured by Total Nasal Symptom Score (TNSS) after nasal allergen challenge (NAC) with Timothy Grass extract at week 17. The secondary objectives of the study are: * To assess whether 16 weeks of treatment with dupilumab as compared to placebo reduces provoked allergic rhinitis symptoms, as measured by TNSS after nasal allergen challenge (NAC) with Timothy Grass extract * To assess whether 16 weeks of treatment with dupilumab as compared to dupilumab + SCIT reduces provoked allergic rhinitis symptoms, as measured by TNSS after nasal allergen challenge (NAC) with Timothy Grass extract * To assess changes in serum Timothy-grass-specific immunoglobulin G4 (IgG4), serum Timothy grass-specific immunoglobulin E (IgE), and ratio of serum Timothy Grass-specific IgG4 to IgE over 16 weeks of treatment with dupilumab + SCIT as compared to SCIT monotherapy * To evaluate the safety and tolerability of 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass SCIT
Conditions Studied
Interventions
- DRUG Dupilumab
- DRUG Timothy Grass SCIT
- DRUG Placebo matching dupilumab
- DRUG Placebo matching SCIT
Study Locations (17)
Ontario
- Regeneron Investigational Site — Kingston
- Regeneron Investigational Site — Mississauga
- Regeneron Investigational Site — Ottawa
- Regeneron Investigational Site — Toronto
California
- Regeneron Investigational Site — Los Angeles
- Regeneron Investigational Site — Mountain View
- Regeneron Investigational Site — Walnut Creek
Massachusetts
- Regeneron Investigational Site — Andover
- Regeneron Investigational Site — North Dartmouth
Maryland
- Regeneron Investigational Site — Baltimore
Missouri
- Regeneron Investigational Site — St Louis
Nebraska
- Regeneron Investigational Site — Bellevue
Oregon
- Regeneron Investigational Site — Portland
Rhode Island
- Regeneron Investigational Site — East Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2018-06-07 |
| Est. Completion | 2019-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03558997
The ClinicalTrials.gov registry entry for NCT03558997 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 290 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 4 interventions — of which Dupilumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03558997 reports 17 study locations spanning 11 distinct geographic areas — top geographies include Ontario, California, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03558997 about?
NCT03558997 is a clinical study titled "Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy". The primary objective is to assess whether 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass Subcutaneous Immunotherapy (SCIT) improves upon the efficacy of Timothy Grass SCIT to reduce provoked allergic rhinitis symptoms, as measured by Total Nasal Symptom Score (TNSS) after nasal...
What is the current status of trial NCT03558997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2018-06-07. Estimated completion is 2019-06-13.
What conditions does trial NCT03558997 study?
This clinical trial studies the following conditions: Allergic Rhinitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03558997?
The interventions under investigation include: Dupilumab (DRUG), Timothy Grass SCIT (DRUG), Placebo matching dupilumab (DRUG), Placebo matching SCIT (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03558997?
This trial is sponsored by Regeneron Pharmaceuticals, which has 290 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03558997 being conducted?
This trial has 17 study locations across California, Maryland, Massachusetts, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.